Copertina

Therapeutic Exhaustion After Upfront Androgen Receptor Signaling Inhibitor: A Hidden Determinant of Post‐CRPC Survival

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Shengyi Chen, Yuekun Fang, Bin Cheng
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Enhancing Diagnostic Accuracy in Prostate Oncology: A Multidimensional Perspective on Prostate Specific Antigen Density
di: Shengyi Chen, et al.
Pubblicazione: (2025)

Integrating Clinical and Societal Perspectives on Prostate Cancer Research: Addressing Key Limitations and Future Directions
di: Yuekun Fang, et al.
Pubblicazione: (2026)

Evaluation of Second‐Line Treatment for Castration‐Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors
di: Kazuro Kikkawa, et al.
Pubblicazione: (2024)

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
di: Kazuma Yukihiro, et al.
Pubblicazione: (2026)

Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer
di: Marina Nasrin Sharifi, et al.
Pubblicazione: (2025)

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study
di: Himawari Asanuma, et al.
Pubblicazione: (2026)

RETRACTION: Interleukin‐4 Activates Androgen Receptor Through CBP/p300
Pubblicazione: (2025)

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
di: Mitsuhisa Nishimoto, et al.
Pubblicazione: (2025)

pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
di: Piotr Bialas, et al.
Pubblicazione: (2024)

c‐Kit‐Mediated PI3K/AKT and Wnt/β‐Catenin Signaling Drives Resistance to 5α‐Reductase Inhibitors in Benign Prostatic Hyperplasia
di: Jun Zhu, et al.
Pubblicazione: (2025)

Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer
di: Yu‐Hsiang Lin, et al.
Pubblicazione: (2025)

Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer
di: Sudharshanan Balaji, et al.
Pubblicazione: (2026)

RETRACTION: Lin28 Induces Resistance to Anti‐Androgens via Promotion of AR Splice Variant Generation
Pubblicazione: (2026)

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target
di: Jacky T. F. Luk, et al.
Pubblicazione: (2026)

Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey‐Holden Prostate Cancer Academy Meeting
di: Tanya Stoyanova, et al.
Pubblicazione: (2025)

Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
di: Masanori Ishida, et al.
Pubblicazione: (2025)

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High‐Risk Prostate Cancer
di: Hanyang Tao, et al.
Pubblicazione: (2024)

Autocrine Fibroblast Growth Factor Receptor 1 Signaling Activates Lactate Dehydrogenase A‐Aerobic Glycolysis for Advanced Human Prostate Tumor Growth
di: Xiaoming Xu, et al.
Pubblicazione: (2025)

Long‐Term Follow‐Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial
di: Braden Millan, et al.
Pubblicazione: (2025)

Influence of 5‐Alpha Reductase Inhibitors on PI‐RADS Scores and Prostate Cancer Detection: A Systematic Review and Meta‐Analysis
di: Lian Qiong, et al.
Pubblicazione: (2025)

Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy
di: Cem Onal, et al.
Pubblicazione: (2026)

Mycobacterium Tuberculosis: The Hidden Bacteria in Chronic Prostatitis
di: André Avarese Figueiredo, et al.
Pubblicazione: (2025)

Significant Effect of Carbon‐Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High‐Risk Prostate Cancer Patients: A Two‐Center Controlled Trial Compare With X‐Ray External Beam Radiation Therapy
di: Xue Zhao, et al.
Pubblicazione: (2024)

Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation
di: Liang G. Qu, et al.
Pubblicazione: (2025)

Outcome Differences Between Subgroups of Favorable Intermediate Risk Prostate Cancer After Radical Prostatectomy
di: Matthew T. Steidle, et al.
Pubblicazione: (2026)

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis
di: Tomoya Hatayama, et al.
Pubblicazione: (2026)

Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
di: Hyun‐Kyung Ko, et al.
Pubblicazione: (2025)

A body shape index (ABSI) but not body mass index (BMI) is associated with prostate cancer‐specific mortality: Evidence from the US NHANES database
di: Hui‐Chen Ku, et al.
Pubblicazione: (2024)

Hormone Therapy With Salvage Radiotherapy After Radical Prostatectomy: A Systematic Review and Meta‐Analysis
di: Reyhaneh Bayani, et al.
Pubblicazione: (2025)

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
di: Nicholas Fedele, et al.
Pubblicazione: (2025)

Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
di: Muhammet Bekir Hacioglu, et al.
Pubblicazione: (2025)

A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA
di: Penglu Yang, et al.
Pubblicazione: (2025)

Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways
di: Nibrass Taher Abdali, et al.
Pubblicazione: (2025)

Progression‐Free Survival Prediction Performance of ChatGPT: Analysis With Real Life Data in Early and Locally Advanced Prostate Cancer
di: Engin Eren Kavak, et al.
Pubblicazione: (2025)

Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
di: András Horváth, et al.
Pubblicazione: (2025)

EXPRESSION OF CONCERN: Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells
Pubblicazione: (2026)

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
di: Meryam Losee, et al.
Pubblicazione: (2025)

Erratum to “Inhibition of Signaling Downstream of Beta‐2 Adrenoceptor by Propranolol in Prostate Cancer Cells”
Pubblicazione: (2025)

LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy
di: Sangjon Pae, et al.
Pubblicazione: (2025)

LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via the p53 Signaling Pathway
di: Zhe Tang, et al.
Pubblicazione: (2025)